Neoplastic transformation requires the elimination of key tumor suppressors, which may result from E3 ligase-mediated proteasomal degradation. We previously demonstrated a key role for the E3 ubiquitin ligase E6AP in the regulation of promyelocytic leukemia protein (PML) stability and formation of PML nuclear bodies. Here, we report the involvement of the E6AP-PML axis in B-cell lymphoma development.
Introduction
A link between proteasomal degradation and cancer development has been established and a general proteasome inhibitor, Velcade (bortezomib), is in clinical use for the treatment of multiple myeloma and mantle cell lymphoma 1,2 . Deregulation of E3 ubiquitin ligases can be sufficient to suppress the expression and function of key tumor suppressors. For example, the inhibition of p53 as a consequence of Mdm2 amplification is frequently observed in human sarcomas and retinoblastoma [3] [4] [5] . Interestingly, in Human Papilloma Virus (HPV)-infected cells the suppression of p53 is not achieved by Mdm2, but rather by the cellular E6AP (E6-associated protein) ubiquitin ligase, which is recruited to p53 by the HPV-E6 protein [6] [7] [8] .
E6AP is encoded by the UBE3A locus, which is mutated in Angelman Syndrome (AS), a human neurodevelopmental disorder 9 . E6AP was the first mammalian ubiquitin E3 ligase to be identified. It is the prototype of the sub-family of E3 ligases that covalently bind ubiquitin and are characterized by a Cterminal HECT (homologous to the E6AP C terminus) domain 10 .
We have recently demonstrated that E6AP regulates the stability of the promyelocytic leukemia (PML) protein and the formation of PML nuclear bodies (PML-NBs) 11 . PML is a tumor suppressor that was identified as a consequence of the chromosomal translocation of its gene in acute promyelocytic leukemia (APL) 12 . Consistent with the role of PML as a tumor suppressor, PML deficient mice showed abnormally
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From increased susceptibility to carcinogen- 13, 14 and oncogene-induced tumorigenesis 15 . Importantly, PML expression was found to be down-regulated or lost in a variety of human cancer types, including prostate, breast and colon adenocarcinomas 16, 17 . PML protein and the PML-NBs were found to play critical roles in cellular stress responses, including those that elicit apoptosis or cellular senescence [18] [19] [20] [21] . Cellular senescence is emerging as an important mechanism for tumor suppression 22, 23 . It represents a profound arrest of cellular proliferation, accompanied by a distinct set of alterations in the cellular phenotype, such as the formation of senescence-associated heterochromatin foci (SAHF, e.g. H3K9me3) and up-regulation of certain inhibitors of cell growth, such as p21, PAI-1 and p16 24 .
In this study we explored the role of the E6AP-PML axis in HPV-independent cancer development. We chose pre-B/B-cell lymphomagenesis as a model because of the high frequency of PML down-regulation in non-Hodgkin lymphomas (NHL) 16 . For this purpose we employed the well established Eμ-myc transgenic mice, a mouse model for Burkitt Lymphoma and other NHL 25 . We found that the loss of one allele of E6AP significantly delayed Myc-driven B-cell lymphomagenesis and this was accompanied by elevated PML expression and the induction of cellular senescence. Importantly, E6AP expression was observed to be elevated in human Burkitt Lymphoma and cell lines derived from these tumors. Our findings reveal a novel role for the E6AP-PML axis in B-cell lymphomagenesis. This insight may provide a rationale for novel approaches to the treatment of B lymphoma.
Methods

Mice
All mouse experiments were performed in accordance with guidelines administered by the Peter MacCallum Cancer Centre Experimental Animal Ethics Committee. The generation and genotyping of Eμ-myc transgenic mice (backcrossed with C57BL/6 mice for >30 generations) has been previously described 25, 26 . E6AP+/-mice maintained on a C57BL/6 background 11 were crossed with Eμ-myc mice to obtain Eμ-myc/E6AP+/-mice. When these mice were inter-crossed, most Eμ-myc/E6AP-/-mice were aborted, therefore making it impossible to obtain a cohort of Eμ-myc/E6AP-/-animals for analyses of tumor onset and pre-leukemic phenotype. Mice were monitored daily for palpable tumors and for systemic signs of illness, including apathy, breathing difficulties, weight loss, ruffled coats, immobility or hunched posture. Sick mice showing any of these symptoms were euthanized and subjected to necropsy. Stem cell isolation, adoptive transfer and lymphoma monitoring and analysis were undertaken as previously described 27, 28 . Eμ-myc transgenic mice and PML-/-mice were crossed,
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Flow cytometric analysis
Immunophenotyping: Single cell suspensions of freshly isolated lymphomas or lymphoid tissues of pre-leukemic mice were stained with the following antibodies: APC-conjugated monoclonal antimouse B220 (CD45R) (eBioscience), FITC-conjugated anti-mouse IgM, PE-conjugated anti-mouse IgD (BD Pharmingen), PE-conjugated anti-mouse Gr-1, FITC-conjugated anti-mouse Mac-1, FITCconjugated anti-mouse Thy 1.2 (eBioscience). Data were collected using BD FACS Canto 2 flow cytometer and analyzed on FlowJo software. Cell viability assay: The percentages of viable cells were determined by propidium iodide (10 μg/mL) staining of freshly harvested lymphoid cells by FACS analysis (10,000 single cell events were collected using BD FACSCanto 2 flow cytometer and FlowJo software was used to analyze data). Cell cycle analysis: 0.5x10 6 of single cell suspensions of freshly isolated lymphoid cells were fixed by drop-wise addition of 5 ml of ice-cold 95% methanol while slowly vortexing and then placement at 4°C for 24 h. Washed cells were resuspended in 300 μl of PBS-2% FBS containing 10 μg/ml of propidium iodide and 50 μg/ml RNAase A for 25 min prior to analysis (10,000 single cell events were collected using BD FACS Canto 2 flow cytometer and analyzed using Modfit software by Verity Software House). For cell cycle analysis of pre-malignant B lymphoid cells from bone marrow, cells were fixed with 1% paraformaldehyde for 20 min and stained with anti-B220-APC for 30 min, followed by addition of PI and FACS analysis. H3K9me3 analysis.
Freshly isolated cells were fixed with 1% paraformaldehyde for 20 min and stained with anti-B220-APC (eBiosceince) and anti-H3K9me3 antibodies (Abcam, ab8898) for 30 min, washed and incubated with goat anti-rabbit IgG antibodies conjugated with Alexa Fluor 488 (Molecular Probes, Invitrogen) for 1h, followed by FACS analysis. White blood cell counts: Total numbers of leukocytes in the blood were measured using an Advia 120 automated hematology analyzer (Bayer Diagnostics, Tarrytown, NY).
Cell culture
Human Burkitt Lymphoma derived cell lines were cultured in RPMI supplemented with 10% heatinactivated fetal calf serum. Cells were treated with 0.2 μg/μl doxycyclin (Sigma) for induction of shRNA expression vectors (see below). 
Immunofluorescence
Cytospins of cells were immunostained as described previously 11 . Briefly, cells were fixed with 4% paraformaldehyde for 15 min, permeabilized (0.1% Triton X) for 5 min, blocked (1% BSA-PBS) for 20 min, then stained with anti-PML antibodies (Upstate/Sigma) and detected by Alexa Fluor 488 conjugated secondary antibodies (Molecular Probes, Invitrogen). DNA was stained with DAPI. Cells were visualized using BX-51 microscope (Olympus).
Lentivirus and retrovirus production and infection
Third-generation lentiviral vector packaging constructs were generously provided by Dr. Marco Herold (Walter and Eliza Hall Institute, Melbourne, Australia) 30 and consisted of the 3 plasmids pMDLg/pRRE, pMD2.G-VSVg and pRSV-REV. The FH1t-shE6AP expression vector (3 μg) and FH1t-shWobble (3 μg)
were transfected along with the lentivirus packaging plasmids (2 μg of each plasmid) into HEK293T cells and the supernatants were collected 48 and 72 h after transfection. Lymphoma cells (0.5x10 6 ) were incubated with the concentrated viral particles (250 μL) in the presence of polybrene (8 μg/ml) for 6 h in a 12-well plate. Seventy-two hours following infection, cells were sorted based on the expression of reporter GFP by using FACS (Beckton Dickinson FACS DiVa flow cytometer). Retroviral infections were performed as previously described 27 .
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SA-β-galactosidase staining
Cryosections of lymphoid tissue embedded in Tissue-Tek OCT (Sakura Finetek) were cut (8 μm) or cytospins of cells were prepared and stained for SA-β-galactosidase as previously described 31 .
Analysis of human Lymphoma samples
Slides were prepared from formalin-fixed paraffin embedded tissue blocks obtained from diagnostic biopsies. Cases were defined as having Burkitt lymphoma or diffuse large B-cell lymphoma according to the current WHO diagnostic criteria. Immunohistochemical staining was performed using anti-PML (Sigma) and anti-E6AP (Serotec). Images were captured using BX-51 microscope (Olympus).
Statistical Analysis
Animal survival curves were plotted using the Kaplan-Meier method. The log-rank test was used to assess differences and nominal p values were calculated. Statistical t-test was used to calculate p values where indicated.
Results
A partial loss of E6AP significantly delayed the onset of Eμ-myc induced pre-B/B-cell lymphoma
It was previously shown that PML expression is frequently down-regulated or lost in NHL 16 . This downregulation was shown to occur at the protein level 16 . Recently, we demonstrated that E6AP functions as a physiological E3 ligase of PML in a variety of cell types, including lymphoid cells 11 . Therefore, we hypothesized that E6AP plays a critical role in the down-regulation of PML and cellular responses of lymphoid malignancies. Consistent with this notion, we found that B lymphoid cells from the bone marrow of E6AP deficient mice are more susceptible than wt B cells to γ-irradiation-induced apoptosis (Fig. 1A) . To examine the role of the E6AP-PML axis in B-cell lymphomagenesis, we employed the Eμ-myc mice, a well-defined transgenic model for pre-B/B lymphoma development. (Fig. 1C) , diminished enlargement of the spleens (Fig. 1D ) and lymph nodes (Fig. 1E) and by an overall reduction in dissemination of lymphoma cells (Supplemental Fig. S1 ). Collectively, these results show that the loss of one allele of E6AP delayed the onset and reduced the severity of Myc-induced pre-B/B-cell lymphoma. These results support a role for E6AP in the development of Myc-driven B-cell lymphoma.
Interestingly, in the moribund Eμ-myc/E6AP+/-mice we observed invasive infiltrations of lymphoid cells in the liver, lung, kidney and occasionally in the heart, which is likely to be the cause of death of these mice (Supplemental Fig. S2 ). Presumably this infiltration occurred due to the prolonged survival of the mice. (Fig. 3) . In contrast, and consistent with previous studies 25, 26 , the numbers of mature B cells were reduced in the bone marrow and spleens of Eμ-myc mice compared to wt controls (Fig. 3) . These results indicate that E6AP deficiency attenuates Myc-induced lymphomagenesis already at the pre-leukemic stage and that the prime effect of E6AP loss is on the pro-B/pre-B cells (Fig. 3) .
Eμ
Attenuated lymphomagenesis in Eμ-myc/E6AP+/-mice is associated with enhanced cellular senescence but not apoptosis Two major tumor suppressor mechanisms, apoptotic cell death and cellular senescence, have been demonstrated to be associated with the attenuation of Myc-driven B-lymphomagenesis [38] [39] [40] . We therefore examined which of these processes was responsible for the extended lymphoma-free survival of Eμ-myc/E6AP+/-mice. Initially, we compared the extent of spontaneous cell death in the malignant lymphomas between the two genotypes of mice. This analysis was also extended to pre-malignant BMderived B lymphoid cells from young pre-leukemic mice of both genotypes. In both cases, this analysis revealed no significant differences in the extent of apoptosis between control Eμ-myc and Eμ-For personal use only. on October 31, 2017. by guest www.bloodjournal.org From myc/E6AP+/-pre-B/B lymphomas (Fig. 4A) , or between BM-derived pre-malignant B cells from the two genotypes ( Fig. 4B) . Next, we compared the effect of E6AP deficiency on the cell cycle distribution of the lymphomas and the pre-malignant BM-derived B lymphoid cells. This revealed a significant reduction in proliferating cells with a corresponding increase in cells within the G1 and G2/M phases of the cell cycle in the Eμ-myc/E6AP+/-pre-B/B lymphomas compared to the control Eμ-myc lymphomas (Fig. 4C) .
Similarly, BM-derived pre-malignant B lymphoid cells from young Eμ-myc/E6AP+/-mice had fewer cells in S phase and more cells within the G1 and G2/M stages of the cycle compared to their counterparts from young control Eμ-myc animals (Fig. 4D ). Given that cell cycle arrest is the major hallmark of cellular senescence, we compared the extent of senescent cells between the pre-B/B lymphomas of the two genotypes using staining for β-Gal (SA-β-Gal), a commonly used marker for detection of senescent cells. 
Up-regulation of PML and enhanced formation of PML-NB in lymphoid cells of Eμ-myc/E6AP+/-mice
In view of our previous findings that E6AP is the E3 ligase of PML 11 , we hypothesized that a partial loss of E6AP expression in the Eμ-myc mice may result in the elevation of PML expression and enhanced formation of PML-NBs. We therefore compared PML expression in lymphoma cells derived from both genotypes of mice. As predicted, we found elevated levels of PML expression in Eμ-myc/E6AP+/-lymphoma cells compared to control Eμ-myc lymphoma cells (Fig. 6A ). This increase in PML protein levels in Eμ-myc/E6AP+/-lymphoma cells correlated with the accumulation of PML-NBs (Fig. 6B ).
Furthermore, we found that the levels of PML were already elevated in the pre-malignant B lymphoid cells of young Eμ-myc/E6AP+/-mice as compared with their counterparts from control Eμ-myc mice ( transduced HSC from PML-/-mice promoted more rapid lymphoma formation in recipient mice compared to Myc transduced control (wt) HSC (Fig. 6G ). As controls we used Myc transduced HSC from p53-/-mice, which also caused rapid lymphoma development in transplant recipients. These experiments provide solid evidence for the critical tumor suppressive function of PML in Myc-induced B cell lymphomagenesis.
E6AP expression is elevated in Burkitt Lymphomas
Our findings demonstrate the involvement of E6AP in pre-B/B lymphomagenesis in a mouse model.
Analysis of E6AP expression levels revealed elevated expression of E6AP in a subset of Eμ-myc and Eμ-myc/E6AP+/-lymphomas (Supplemental Fig. S9 ), supporting the pro-oncogenic role of E6AP in B-cell lymphomagenesis. To investigate whether E6AP is also involved in human B cell lymphoma development, we examined its expression in a cohort of primary Burkitt Lymphomas.
Immunohistochemical analysis revealed that in 12 out of 20 samples examined (60%) the expression levels of E6AP were elevated compared to normal lymphoid tissues ( Fig. 7A and Supplemental Fig. S10 ).
Interestingly, 6/12 (50%) of Burkitt's patient lymphoma samples with high E6AP had correspondingly low levels of PML expression (Fig. 7A ). The analysis of samples of Diffused Large Cell Lymphoma (DLCL) revealed that in 18% of the samples (7/39; 18%) moderate or elevated levels of E6AP inversely correlated with reduced PML levels (Supplemental Fig. S11 ). Furthermore, we also assessed the expression levels of E6AP in cell lines derived from human Burkitt Lymphomas, DLCL and Follicular Lymphomas. We found that in 4 out of 14 (29%) cell lines analyzed the expression levels of E6AP were elevated, while in 2 additional cell lines (14%) E6AP expression was moderately elevated (Fig. 7B) .
Strikingly, elevated levels of E6AP expression inversely correlated with down-regulation of PML expression (Fig. 7B) . Interestingly, the observed correlation was found to be specifically associated with cMyc over-expression in the majority of these lymphoma derived cell lines (Fig. 7B ). These results demonstrate the elevation of E6AP expression in a significant proportion of human Burkitt Lymphoma cases, indicating that E6AP may play a role in the development and/or sustained growth of these hematological cancers. Furthermore, the correlation between elevated E6AP expression and downregulation of PML supports our finding that E6AP negatively regulates PML, at least within certain B-cell lymphomas.
Down-regulation of E6AP restores PML expression and induces cellular senescence in human Burkitt Lymphoma derived cell lines
To establish a functional interaction between E6AP and PML in human Burkitt Lymphoma, it was important to ascertain whether the down-regulation of the relatively high levels of E6AP in the cell lines derived from these tumors (Fig. 7B) could restore PML expression. For this purpose we used an inducible shRNA expression vector to knock down E6AP expression in the J-1 and LS-92 Burkitt Lymphoma derived cell lines, which express elevated levels of E6AP. Strikingly, E6AP knockdown resulted in restoration of PML expression (Fig. 7C) and formation of PML-NBs in these cells (Fig. 7D) . To examine the consequences of PML restoration on these Burkitt Lymphoma derived cell lines, we compared their cell cycle distribution in the presence or absence of E6AP shRNA expression. As shown in Fig. 7E , downregulation of E6AP increased the proportion of cells in G1 with a corresponding decrease of cycling cells (in the S phase), resulting in a reduction in cell proliferation with no impact on cell viability (Supplemental Fig. S12 ). This effect coincided with a significant number of cells showing hallmarks of senescence (Fig.   7F ). These results support our hypothesis that elevated levels of E6AP with the resulting down-regulation of PML and inhibition of cellular senescence promote the growth of human Burkitt Lymphoma cells.
Discussion
Restoration of the activity of tumor suppressors is an attractive approach for cancer treatment 23, 43 . One avenue by which this may be achieved is by protecting key tumor suppressors from proteasomal degradation. Indeed, deregulation of E3 ligases can be sufficient to block the activity of tumor suppressors. This is best exemplified by the amplification of the E3 ligase Mdm2, which negates the pressure for p53 mutations in one third of human sarcomas 4,5 . This study builds on our recent finding that E6AP functions as an E3 ligase for PML
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. Since PML expression is frequently down-regulated or lost in many cancer types 16, 44 , we examined the role of the E6AP-PML regulatory pathway in tumorigenesis, particularly the development of pre-B/B lymphoma. Using the Eµ-myc transgenic mouse model, in which over-expressed Myc deregulates proliferation of B lymphoid cells, thereby promoting pre-B/B lymphoma development 25,26 , we show that haplo-insufficiency of E6AP reduces disease burden and significantly prolongs the survival of these mice (Fig. 1) . Effects on apoptotic cell death are well known to impact on Myc-induced lymphomagenesis, in particular when p53 activity has been triggered, as in the case of haplo-insufficient Mdm2 mice 36, 38, 45 . Surprisingly, however, the partial loss of E6AP sensitized Mycexpressing B cells to undergo senescence rather than apoptosis (Figs. 5 and 6 ). Thus far, cellular senescence has been demonstrated in Myc-driven B lymphomas in the context of the p53 R172P mutation,
which disables the pro-apoptotic activity of p53, and in response to TGF-β 39,40 . Interestingly, the induction of senescence by E6AP haplo-insufficiency is already evident in the pre-malignant B lymphoid cells (Fig.   5 ). Therefore, this response is likely to contribute to the observed decrease in the number of pre-malignant B lymphoid cells (Fig. 3) and the prolonged survival of these animals (Fig. 1) . The detection of only relatively low numbers of senescent cells in Eμ-myc/E6AP+/-mice is probably due to the rapid clearance of these cells by the immune system 41, 42 . Consistent with our previous finding that E6AP regulates PML stability 11 , we found that Eμ-myc lymphoma cells as well as pre-malignant Myc over-expressing B lymphoid cells with a partial loss of E6AP had elevated levels of PML and PML-NBs, consistent with their increased propensity to undergo cellular senescence (Fig. 6) . The PML tumor suppressor plays a key role in the induction of cellular senescence in response to diverse stimuli [19] [20] [21] 46 . Remarkably, multiple key markers implicated in PMLinduced senescence
20
, including p16, p21 and PAI-1, were elevated in E6AP deficient pre-B/B lymphoma cells (Fig. 6 ). PML-NBs are critical for the activation of chromatin remodeling molecules (e.g. HIRA, HP1) required for the formation of SAHF that are responsible for permanent growth arrest [47] [48] [49] [50] .
Importantly, consistent with a role of PML in heterochromatin silencing, we detected enhanced methylation of histone H3 (H3K9me3) in Eμ-myc/E6AP+/-lymphoma cells compared to control Eμ-myc lymphoma cells (Fig. 5) . Our results therefore support a role for E6AP in the regulation of PML-mediated senescence in Myc-induced B-lymphomagenesis. The critical role of PML as a tumour suppressor in Mycinduced lymphoma was confirmed by the accelerated B-lymphomagenesis caused by a loss of one or both alleles of PML (Fig. 6 ).
To extend our findings to human malignancy, we screened a cohort of primary human Burkitt Lymphoma cases and a set of cell lines derived from such tumors, for levels of E6AP and PML. Remarkably, we found that E6AP expression levels were elevated in 43% of the human Burkitt Lymphoma derived cells lines ( Fig. 7B ) and in 60% of the primary human Burkitt Lymphomas (Fig. 7A ). In line with our previous report 11 and the observations in the Eµ-myc pre-B/B lymphomas, we found that in a subset of these samples with elevated expression of E6AP, the levels of PML expression were correspondingly low (Fig.   7 ). This supports our notion that E6AP regulates cellular senescence by controlling the levels of PML, at least in a subset of B-cell lymphomas. To demonstrate this functional interaction more directly, we downregulated E6AP in two Burkitt Lymphoma cell lines that over-expressed this protein. Remarkably, this E6AP down-regulation restored PML expression levels and the formation of PML-NBs, leading to a concomitant increase in cellular senescence (Fig. 7C-F) . This strongly supports the involvement of the 1 4
E6AP-PML axis in the regulation of cellular senescence in B lymphoma cells. Induction of cellular senescence is emerging as an important mechanism for cancer therapy 23, 24 . Recent studies demonstrated that senescence is a key process underlying tumor regression in response to oncogene inactivation, reactivation of tumor suppressors or certain chemotherapeutic interventions 23, 24 . Moreover, restoration of PML expression has been shown to attenuate tumor development in a xenograft model 51, 52 . Our findings provide a rationale for targeting the E6AP-PML axis for treating B-cell lymphomas by triggering PMLmediated cellular senescence. This is of particular interest, given that PML expression is down-regulated in a variety of human cancers, including NHL, and that this occurs largely at the protein levels 16, 44 .
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